Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$1.17 USD
-0.12 (-9.30%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $1.16 -0.01 (-0.85%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 28% (71 out of 252)Zacks Sector Rank
Top 25% (4 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.29 | 1.35 | 9.99 |
Current Quarter Estimate | -0.04 | 7.43 | 59.00 |
Year Ago Quarter Estimate | -0.03 | 0.12 | 50.37 |
Next Quarter Estimate | -0.04 | 7.81 | 60.00 |
Next Year Estimate | -0.15 | 37.76 | 238.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | -50.00 | 13.60 | 20.73 |
Next Year | 16.67 | 12.40 | 13.55 |
Last 5 Years | NA | 1.00 | 9.00 |
Next 5 Years | NA | 20.40 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -2.18 |
Price/Book (MRQ) | 3.64 | 2.22 |
Price/Cash Flow (MRFY) | NA | 14.19 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -240.20% | -114.01% |
Return on Equity (TTM) | -31.96% | -46.54% |
Debt to Equity (MRQ) | 0.00 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.